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Background: Both the human immunodeficiency virus (HIV) and hepatitis C virus (HCV), either alone or as
coinfections, persist in their hosts by destroying and/or escaping immune defenses, with high morbidity as
consequence. In some cases, however, a balance between infection and immunity is reached, leading to prolonged
asymptomatic periods. We report a case of such an indolent co-infection, which could be explained by the
development of a peculiar subset of Natural Killer (NK) cells.
Results: Persistently high peripheral levels of CD56+ NK cells were observed in a peculiar hemophiliac HIV/HCV
co-infected patient with low CD4 counts, almost undetectable HIV viral load and no opportunistic infections.
Thorough analysis of NK-subsets allowed to identify a marked increase in the CD56bright/dim cell ratio and low
numbers of CD16+/CD56- cells. These cells have high levels of natural cytotoxicity receptors but low NCR2
and CD69, and lack both CD57 and CD25 expression. The degranulation potential of NK-cells which correlates
with target cytolysis was atypically mainly performed by CD56bright NK-cells, whereas no production of interferon
γ (IFN-γ) was observed following NK activation by K562 cells.
Conclusions: These data suggest that the expansion and lytic capacity of the CD56bright NK subset may be
involved in the protection of this « rare » HIV/HCV co-infected hemophiliac A patient from opportunistic infections
and virus-related cancers despite very low CD4+ cell counts.
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Hemophiliac patients have been especially at risk of infec-
tions by blood-borne viruses before drastic measures were
taken to control transfused blood products. We report the
peculiar case of a hemophiliac patient co-infected by both
human immunodeficiency virus (HIV) and hepatitis C
virus (HCV) who developed unusual immune responses.* Correspondence: claude.capron@apr.aphp.fr
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reproduction in any medium, provided the orThe course of HIV infection is in most cases quite
straightforward. Both the cytopathic effect of the virus
and cytotoxic immune responses contribute to the de-
struction of infected CD4+ cells. The classically reverted
CD4+/CD8+ ratio is accompanied with high viral loads.
In most cases, long-term anti-viral therapy results in a
near disappearance of the viral load together with a pro-
gressive increase in CD4+ counts. However, in rare cases,
the viral load may become undetectable while CD4+
counts remain low [1].
Approximately 15–30% of HIV patients present HCV
co-infection. HCV is also the most common cause of
chronic liver disease and leading cause of death in
hemophiliacs [2]. Co-infection usually leads to a moreLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pared to single HCV infection while the effect of HCV
on HIV infection is still debated [3,4].
The peculiar case that we report is of a long-term clin-
ically asymptomatic hemophiliac patient co-infected
with HIV and HCV since childhood. It sheds new light
on the possible immunological adaptation mechanisms
liable to control HIV infection. A role of Natural Killer
(NK) cells in the non-progression of both infections is
likely according to the unusual NK-subsets observed in
this patient [5].
Case presentation
A 38 years-old moderate hemophiliac A male patient
was diagnosed to be co-infected with HIV (Subtype B,
CCR5+) and HCV (Subtype 4), both transmitted by a
blood transfusion received in 1982 during hip surgery
for a fracture. Diagnoses of these infections were re-
spectively ascertained in 1988 and 1998.
Since 1989, he received different lines of anti-retroviral
treatment (ART) then HAART (Highly Active Anti-
Retroviral Therapy) with poor compliance, voluntary
interruption until 2008, and correct compliance since
then. A 215S mutation of the HIV virus reverse tran-
scriptase, which induces resistance to the anti-retroviral
drug azidothymidine was consequently identified. His
HCV infection (Metavir score A0A1-F1F2 determined
by biopsy and checked regularly by noninvasive markers
of hepatitis inflammation/fibrosis) was never treated.
Moreover his hepatic assessment, as observed with L-
aspartate aminotransferase (ASAT), L-alanine amino-
transferase (ALAT) and γGT gamma-glutamyltransferase
markers is not so much disrupted (Figure 1A).
The patient received prosthesis of the left eye in 1996
after a paintball accident and a hip replacement in 2011
for osteo-necrosis known since 1982. None of these sur-
geries were accompanied by infectious side effects. In-
deed, over these 30 years and despite an extremely low
number of T lymphocytes, the patient displayed neither
opportunistic infections, nor HIV-related cancer, nor
HCV-hepatitis damages. In 1989 his initial CD4+ T-cells
count was 196/mm3 and since 1995 remains between 5
and 59/mm3 (Figure 1B). HIV viral loads have been
mostly undetectable (below 40 copies/mL) or very low
(matching deliberate HAART interruptions) since 2008
(Figure 1B).
Over the past two years, the immunophenotypic and
functional status [6] of his CD3-CD56+ NK-cells were
explored by multi-parameter flow cytometry (reagents from
Becton Dickinson, MountainView, CA, Figures 2A-D).
Surprisingly, an abnormally high percentage of NK-cells
has been steadily observed, representing approximatively
40% of peripheral lymphocytes and characterized by an ex-
pansion of the CD56bright subset (~30 to 50% of NK-cells)(Figures 2A and 2B). The percentage of CD56bright cells
seems to increase when the number of CD4 decreases
moreover HIV viral load is below 40 copies/ml when % of
CD56bright cells is the more important (Figure 2B). These
cells display high levels of natural cytotoxicity receptors
NCR1 (NKp46), NCR3 (NKp30) and NKG2D compared
to CD56dim cells, and have a low expression of NCR2
(NKp44) and CD69, with no labeling for CD57 nor CD25
(data not shown). The inhibitory CD94/NKG2A receptor is
expressed by all CD56bright cells and a majority of CD56dim
NK-cells while there is a low expression of CD158b on
CD56dim and CD56bright NK-cells and a faint labeling with
CD158a (Figure 2C).
Surprisingly, the NK degranulation potential (% of
CD107a) that correlates with target cytolysis [7,8], usually
exerted by the CD56dim NK subset [9], is here mainly per-
formed by CD56bright NK-cells. Strikingly, these cells did
not produce IFN-γ following NK activation by K562
(Figure 2D).
In addition, no Th1/Th2 cytokines (TNF-α, IFN-γ, IL-
2, IL-4, IL-5, IL-10) have been detected in the patient’s
serum (data not shown).
Discussion
Several studies have reported that in HIV infection, and
even more in HIV/HCV co-infection, NK cells most
often lack CD56 expression and have impaired functions
[10-12], opposite to what was observed in the patient
reported here. However, at least one study [13] reported
a similar quantitative imbalance of CD56bright and
CD56dim NK-cells in HIV or HCV patients as shown
here. Two possibilities could explain this profile. The
first is an alteration in the tissue localization of NK-
subsets in tissues as there could be selective trapping
in the liver in HCV infection or in lymph nodes (LN)
in HIV infection [13]. Secondary lymphoid tissues, and
particularly LN, are important sites for HIV replication
and NK development. In HIV patients, the disruption of
LN architecture could interfere with the numbers of
CD56bright cells reaching the circulation [14], and the in-
crease of circulating CD56bright NKG2A+ cells could thus
be caused by NK activation and release from LN [15,16].
The other hypothesis is that impairment in NK-cell
homeostasis, in HIV and HCV infections, could result
from different behaviors of NK-subsets. An imbalance
between CD56+ NK-subsets could indeed result from an
enhanced production, expansion or survival of the
CD56bright pool accompanied by a decreased generation
or survival of CD56dim NK-cells [17].
When altered CD56dim/bright NK-cell ratios have been
reported in asymptomatic HIV or HCV patients with
low CD4+ counts, viral loads remained detectable
[10,13]. Ironson et al. [16] indeed described a rare group
of HIV patients with very low CD4+ T-cells counts who
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Figure 1 HIV and HCV viral loads, hepatic functions and CD4 count. A: Hepatic functions determined by liver enzyme assays (ASAT: L-
aspartate aminotransferase (light grey circles) (U/L); ALAT: L-alanine aminotransferase (grey squares) (UL/) and γGT: gamma-glutamyltransferase
(triangles)(U/L)) and HCV viral load (black crosses, number of HCV UI/mL) over time. B: Absolute numbers of CD4+ T-cells (grey line, number of
CD4/mm3) and HIV viral load (black line, number of copies/mL; limit of detection: 40 copies/ml) over time.
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http://www.virologyj.com/content/10/1/33displayed prolonged asymptomatic periods. These patients
presented higher NK-cell numbers and cytotoxic potential
than HIV patients with high CD4+ counts. However, un-
like the patient we report upon, they retained an elevated
viral load [16].
The particular immunophenotype observed here, char-
acterized by high CD56bright numbers, recalls that ofNK-cells from low viremic HIV patients with high num-
bers of CD4+ T-cells [14], yet our patient never recov-
ered normal CD4+ counts.
The cytokine microenvironment may also alter the
immunophenotype of NK-cells. Since IL15 and/or IL21
[13,18] regulate NK homeostasis and effector functions,
the absence of IL-15 production could favor CD56bright
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Figure 2 Percentages of Natural Killer (NK) cells and their subsets; lytic potential of NK cells. A: Representative dot plot of
CD16lowCD56bright; CD16+CD56bright, CD16+, CD56dim and CD16brightCD56- cells. Based on forward and side scatter analysis, cells were first gated
on lymphocytes (not shown) and then on CD3- cells. B: Absolute numbers of CD4+ T-cells (light grey line, number of CD4/mm3), % of CD56bright
in total CD56 NK cells (dark grey line, % of CD56bright cells) and HIV viral load (black line, number of copies/mL) during one year. C: Representative
dot plots of the expression of activating and inhibitory receptors on NK-cells among CD56+ CD16+/− cells. D: Representative dot plots of CD107a
degranulation and IFN-γ secretion on CD56dim and CD56bright cells, following PBMC activation by K562.
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http://www.virologyj.com/content/10/1/33NK-cells and thus induce a change in CD56bright/dim
proportions. Indeed, no IL-15 could be detected in the
patient’s serum.
NKp44, usually induced on activated NK-cells, has
been shown to be overexpressed by HIV patients with
low CD4+ T-cells [19] and to be involved in CD4+ T-cell
lysis [20,21]. However, in the present case, NKp44 is
faintly expressed by CD56bright NK-cells, thus likely not
involved in CD4+ depletion through this pathway. High
NKG2A expression, as observed here, has conversely
been associated with the escape of HIV infected CD4+
T-cells from NK-cell killing [22]. We cannot however
exclude a lysis of CD4 cells by NK-cells, since the
patient’s CD56bright cells were clearly efficiently activated
by the K562 cell line [7,8].The replacement of CD56+ NK-cells by functionally
defective CD56- NK-cells is one of the mechanisms
underlying the impaired NK response commonly
observed in HIV and HIV/HCV patients [23,24]. How-
ever, in the present case, CD56-CD16+ cell numbers are
low and CD56bright cells are functional, suggesting that
an unusual scenario is involved to contain HIV and pos-
sibly HCV [5] infection.
As a whole, the functional status of this patient’s NK-
cells is different from that observed in HIV or HCV
infected patients for whom NK cytotoxicity relies on the
CD56dim compartment [10,13].
It is finally of interest to note that hemophiliac
patients with HCV or HCV/HIV infections have been
shown to be at risk of developing cancers [25]. The
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be involved in the protection of this patient towards the
development of secondary complications linked to HIV/
HCV infections.Conclusions
It is well established that HCV disease progresses more
rapidly in HCV/HIV-1 co-infected patients [3,26-28].
This co-infection is probably also associated with a more
rapid progression of HIV disease [29,30]. Although the ef-
ficacy of anti-retroviral therapy has increased the life ex-
pectancy of HIV-infected individuals, the management of
co-infected patients is still a challenging field. Indeed, co-
infection complicates the treatment of both infections due
to impaired liver function, drug toxicity, reduced respon-
siveness to HCV treatment with pegylated infereron and
ribavirin, and poor immune restoration upon ART [31].
HCV/HIV co-infection represents a challenge for the im-
mune system and NK-cells are probably important at all
stages to manage the viral attack.
Despite very low CD4+ T cell counts, the special long-
term HIV/HCV co-infected hemophiliac patient that we
describe here is healthy and presents neither opportunistic
infections nor any sign of virus-related cancer. This patient
shows unexpected NK-cell populations characterized by
an abnormally high proportion of the CD56bright NCR+
NK-cell subset. These cells are also unusually endowed
with cytotoxic potential and no IFN-γ production. It is
highly suspected that these cells are involved in both the
destruction of his CD4+ T-cells and viral control. Such
control of the viral load is a rare case of immunological
adaptation to infections that outlines the plasticity of the
immune system when confronted with unusual aggres-
sions from the environment.
The successful control established by this patient over
both his HIV and HCV infections and to avoid oppor-
tunistic infections sheds new light on the compliance of
the immune system together with HAART and opens
new original research fields in order to strengthen con-
trol mechanisms for the management of viral infections
via the enhancement of innate immunity [32].Ethical approval
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Abbreviations
NK: Natural Killer; HIV: Human immunodeficiency virus; HCV: Hepatitis C virus;
NCR: Natural cytotoxicity receptor; KIR: Killer-cell immunoglobulin-like
receptors; Th: Lymphocyte T helper; TNFα: Tumor necrosis factor;
IFNγ: Interferon; IL: Interleukin (IL2, IL4, IL5, IL10); ART: Antiretroviral treatment;
LN: Lymph node.Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
Giulia Fregni and Valérie Jalbert performed experiments. Anaenza Freire Maresca,
Anne Caignard and Marie C Béné drafted the manuscript or revised it. Daniel
Scott-Algara, Elisabeth Bordé Cramer and Elisabeth Rouveix gave final approval of
the version to be published. Claude Capron initiated and supervised the study,
wrote and edited the manuscript. All authors read and approved the final
manuscript.
Authors’ information
Giulia Fregni is a Ph D student; Valérie Jalbert is a laboratory technician; Anne
Caignard and Daniel Scott-Algara are researchers; Marie C Béné, Elisabeth Bordé
Cramer and Elisabeth Rouveix are university professors; Anaenza Freire Maresca is
a clinician; Claude Capron is a university assistant professor.
Acknowledgments
The authors thank the Immunobiology platform of Institut Cochin for seric
cytokine assays.
Author details
1Inserm U1016, Institut Cochin, Département d’Hématologie et
d’Immunologie, Paris, France. 2Université Paris Descartes Sorbonne Paris Cité,
CNRS (UMR8104), Paris, France. 3Service d’Hématologie et d’Immunologie,
Hôpital Ambroise Paré, Boulogne-Billancourt, France. 4UFR des Sciences et de
la Santé Paris Ile-de-France Ouest, Université de Versailles St Quentin en
Yvelines, St Quentin en Yvelines, France. 5Laboratoire d’Hématologie,
Hôtel-Dieu-CHU, Nantes, France. 6Service de Médecine Interne, Hôpital
Ambroise Paré, Boulogne-Billancourt, France. 7Unité de Régulation des
Infections Rétrovirales, Institut Pasteur, Paris, France. 8Institute of Pathology,
Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medecine,
University of Lausanne, Lausanne, Switzerland.
Received: 14 November 2012 Accepted: 23 January 2013
Published: 26 January 2013
References
1. Piketty C, Castiel P, Belec L, Batisse D, Si Mohamed A, Gilquin J, et al:
Discrepant responses to triple combination antiretroviral therapy in
advanced HIV disease. AIDS 1998, 12:745–750.
2. Ragni MV, Moore CG, Soadwa K, Nalesnik MA, Zajko AB, Cortese-Hassett A,
et al: Impact of HIV on liver fibrosis in men with hepatitis C infection and
haemophilia. Haemophilia 2011, 17:103–111.
3. Koziel MJ, Peters MG: Viral hepatitis in HIV infection. N Eng J Med 2007,
356:1445–1454.
4. Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, et al:
HIV-induced immunodeficiency and mortality from AIDS-defining and
non-AIDS-defining malignancies. AIDS 2008, 22:2143–2153.
5. Krämer B, Körner C, Kebschull M, Glässner A, Eisenhardt M, Nischalke HD,
et al: NKp46(High) expression defines a NK cell subset that is potentially
involved in control of HCV replication and modulation of liver fibrosis.
Hepatology 2012, 56(4):1201–1213.
6. Alter G, Malenfant JM, Delabre RM, Burgett NC, Yu XG, Lichterfeld M, et al:
Increased natural killer cell activity in viremic HIV-1 infection. J Immunol
2004, 173:5305–5311.
7. Alter G, Malenfant JM, Altfeld M: CD107a as a functional marker for the
identification of natural killer cell activity. J Immunol Methods 2004, 294:15–22.
8. Aktas E, Kucuksezer UC, Bilgic S, Erten G, Deniz G: Relationship between
CD107a expression and cytotoxic activity. Cell Immunol 2009, 254:149–154.
9. Nagler A, Lanier LL, Cwirla S, Phillips JH: Comparative studies of human FcRIII-
positive and negative natural killer cells. J Immunol 1989, 143:3183–3191.
10. Alter G, Teigen N, Davis BT, Addo MM, Suscovich TJ, Waring MT, et al:
Sequential deregulation of NK cell subset distribution and function
starting in acute HIV-1 infection. Blood 2005, 106:3366–3369.
11. Gonzalez VD, Falconer K, Michaelsson J, Moll M, Reichard O, Alaeus A, et al:
Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion
by antiviral treatment with pegylated IFNalpha and ribavirin.
Clin Immunol 2008, 128:46–56.
Fregni et al. Virology Journal 2013, 10:33 Page 6 of 6
http://www.virologyj.com/content/10/1/3312. Hong HS, Eberhard JM, Keudel P, Bollmann BA, Ahmad F, Ballmaier M, et al:
Phenotypically and functionally distinct subsets contribute to the expansion
of CD56-/CD16+ natural killer cells in HIV infection. AIDS 2010, 24:1823–1834.
13. Meier UC, Owen RE, Taylor E, Worth A, Naoumov N, Willberg C, et al:
Shared alterations in NK cell frequency, phenotype, and function in
chronic human immunodeficiency virus and hepatitis C virus infections.
J Virol 2005, 79(19):12365–12374.
14. Mantegani P, Tambussi G, Galli L, Din CT, Lazzarin A, Fortis C: Perturbation
of the natural killer cell compartment during primary human
immunodeficiency virus 1 infection primarily involving the CD56 bright
subset. Immunology 2010, 129:220–233.
15. Fogli M, Costa P, Murdaca G, Setti M, Mingari MC, Moretta L, et al: Significant
NK cell activation associated with decreased cytolytic function in peripheral
blood of HIV-1-infected patients. Eur J Immunol 2004, 34:2313–2321.
16. Ironson G, Balbin E, Solomon G, Fahey J, Klimas N, Schneiderman N, et al:
Relative preservation of natural killer cell cytotoxicity and number
in healthy AIDS patients with low CD4 cell counts. AIDS 2001, 15:2065–2073.
17. Cooper MA, Fehniger TA, Caligiuri MA: The biology of human natural
killer-cell subsets. Trends Immunol 2001, 22:633–640.
18. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA,
et al: Interleukin 21 and its receptor are involved in NK cell expansion
and regulation of lymphocyte function. Nature 2000, 408:57–63.
19. Vieillard V, Strominger JL, Debre P: NK cytotoxicity against CD4+ T cells
during HIV-1 infection: a gp41 peptide induces the expression of an
NKp44 ligand. Proc Natl Acad Sci U S A 2005, 102:10981–10986.
20. Freud AG, Becknell B, Roychowdhury S, Mao HC, Ferketich AK, Nuovo GJ,
et al: A human CD34(+) subset resides in lymph nodes and differentiates
into CD56bright natural killer cells. Immunity 2005, 22:295–304.
21. Smith BA, Gartner S, Liu Y, Perelson AS, Stilianakis NI, Keele BF, et al: Persistence
of infectious HIV on follicular dendritic cells. J Immunol 2001, 166:690–696.
22. Zhang R, Xu J, Hong K, Yuan L, Peng H, Tang H, et al: Increased NKG2A
found in cytotoxic natural killer subset in HIV-1 patients with advanced
clinical status. AIDS 2007, 21:S9–S17.
23. Mavilio D, Benjamin J, Daucher M, Lombardo G, Kottilil S, Planta MA, et al:
Natural killer cells in HIV-1 infection: dichotomous effects of viremia on
inhibitory and activating receptors and their functional correlates.
Proc Natl Acad Sci U S A 2003, 100:15011–15016.
24. Mavilio D, Lombardo G, Benjamin J, Kim D, Follman D, Marcenaro E, et al:
Characterization of CD56-/CD16+ natural killer (NK) cells: a highly
dysfunctional NK subset expanded in HIV-infected viremic individuals.
Proc Natl Acad Sci U S A 2005, 102:2886–2891.
25. Tagliaferri A, Di Perna C, Santoro C, Schinco P, Santoro R, Rossetti G, et al:
Cancers in Patients with Hemophilia: a Retrospective Study from the Italian
Association of Hemophilia Centers. J Thromb Haemost 2012, 10:90–95.
26. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al: Increasing
mortality due to end-stage liver disease in patients with human
immunodeficiency virus infection. Clin Infect Dis 2001, 32:492–497.
27. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al: Clinical
progression, survival, and immune recovery during antiretroviral therapy
in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV
Cohort Study. Lancet 2000, 356:1800–1805.
28. Piroth L, Duong M, Quantin C, Abrahamowicz M, Michardiere R, Aho LS,
et al: Does hepatitis C virus co-infection accelerate clinical and
immunological evolution of HIV-infected patients? AIDS 1998, 12:381–388.
29. Daar ES, Lynn H, Donfield S, Gomperts E, O'Brien SJ, Hilgartner MW, et al:
Hepatitis C virus load is associated with human immunodeficiency virus
type 1 disease progression in hemophiliacs. J Infect Dis 2001, 183:589–595.
30. Piroth L, Grappin M, Cuzin L, Mouton Y, Bouchard O, Raffi F, et al: Hepatitis C
virus co-infection is a negative prognostic factor for clinical evolution in
human immunodeficiency virus-positive patients. J Viral Hepat 2000, 7:302–308.31. Braitstein P, Palepu A, Dieterich D, Benhamou Y, Montaner JS: Special
considerations in the initiation and management of antiretroviral therapy
in individuals coinfected with HIV and hepatitis C. AIDS 2004, 18:2221–2234.
32. Gupta N, Arthos J, Khazanie P, Steenbeke TD, Censoplano NM, Chung EA,
et al: Targeted lysis of HIV-infected cells by natural killer cells armed and
triggered by a recombinant immunoglobulin fusion protein: implications
for immunotherapy. Virology 2005, 332:491–497.
doi:10.1186/1743-422X-10-33
Cite this article as: Fregni et al.: High number of CD56bright NK-cells and
persistently low CD4+ T-cells in a hemophiliac HIV/HCV co-infected
patient without opportunistic infections. Virology Journal 2013 10:33.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
